Homework Help is Here – Start Your Trial Now!
Math
Probability
TABLE ISummary of reuts of moecuar ougnostic tests ana tne rapia antigen tt for coviD-o usea on sef-conecta aasampes Total no. () of samples (95% confidence Interval) at the indicated time of colleetion since the onset of symptoms Test and primer set. method, or target Total no. (%) of samples (95% confidence Interval) (n Earty phase (S9 days) (n - 61) Late phase (9 days) (n 27) 103) No specifie time (asymptomatie) (n 15) RT-OPCR LDT 57 (934) (84.1-98 2) 17 (63.0) (424-80.6) 84 (01.6) (727-88 5) 10 166.7) (384-08.2) 54 (88.S) (778-95 2) 14 (S19) (319-71.3) 8 (53.3) (26.6-78.7) N-1 set 76 (738) (642-82.0) 83 (80 6) (716-877) 16 (59 3) (38.8-77.6) N-2 set 57 (934) (841-98 2) 10 (66.7) (384-88 2) cobas SARS-Cov2 test 83 (80 6) (716-877) 56 (918) (819-97.3) 18 (66.7) (46.0-835) 9 (60.0) (323-83.7) 54 (88 5) (778-95 2) 8 IS3.3 (26.6-78.7) Target 1 76 (73.8) (64 2-820) 14 (519) (319-713) Target 2 83 (80.6) (64.2-820) 56 (91.8) (819-973) 18 (667) (46.0-83.5) 9 160.0) (323-83.7) Direct RT-aPCR Method A 79 (76.7) (673-84 5) 53 (86 9) (758-94 2) 16 (593) (388-776) 10 (66.7) (384-88 2) e1 (78.6) (695-061) 55 (90 2) (798-96 3) 9 (60.0) (323-03.7) Method B 17 (63.0) (424-80 6) 80 (777) (684-0s3) 54 (88 5) (778-953 N-1 17 (63.0) (424-80.6) 9 (60.0) (323-83.7) set 48 (78.7) (66.3-88.) 8 (29 6 (13.8-50 2) N-2 63 161.2) (511-70.6) 7 (46.7) (213-73.4) set 52 (SO.5) (405-60.5) 6 (22.2) (8.6- 423) 6 (40.01 (16.3-67.7) Method c 40 (65.6) (523-773) 9 14 8 (70- 26.1) 15 (14.6) (8.4-229) 274) (10- 24.3) N-1 4 (26.7 (78-551) set N-2 51 (49 5) (39.5-59.5) 40 (65,6) 6 (22.21 (6.6- 5 (33.3) (18-616) RT-LAMP 73 (70.9) (611-79.4) 9 (60.0) (323-837) 52 (852) (73.8-93.0) 12 (44 4) (25.5-647) 8 (13.1) (5.8- 24 2) Rapid antigen test 12 1.7) (62-19.5) 2(74) (1.0- 24.3) 2 033) (17-405) LDT, iaboratory-developed test. Method A. SARS-Cov-2direct detection RT-aPCR iet TakaRa Bio inc, Kusatsu, Japan). Method B, Ampdirect 2o19 novel coronavirus detection kit (Snimadzu Corporation, Kyoto, Japan). Method C, SARS-Cov-2 detection kit Toyobo, Osaka, Japan). Primer and probe set recommended by the National institute of infectious Diseases (NID) in Japan Primer and probe set recommended by the Centers for Disease Control and Prevention (CDC) in the United States

TABLE ISummary of reuts of moecuar ougnostic tests ana tne rapia antigen tt for coviD-o usea on sef-conecta aasampes Total no. () of samples (95% confidence Interval) at the indicated time of colleetion since the onset of symptoms Test and primer set. method, or target Total no. (%) of samples (95% confidence Interval) (n Earty phase (S9 days) (n - 61) Late phase (9 days) (n 27) 103) No specifie time (asymptomatie) (n 15) RT-OPCR LDT 57 (934) (84.1-98 2) 17 (63.0) (424-80.6) 84 (01.6) (727-88 5) 10 166.7) (384-08.2) 54 (88.S) (778-95 2) 14 (S19) (319-71.3) 8 (53.3) (26.6-78.7) N-1 set 76 (738) (642-82.0) 83 (80 6) (716-877) 16 (59 3) (38.8-77.6) N-2 set 57 (934) (841-98 2) 10 (66.7) (384-88 2) cobas SARS-Cov2 test 83 (80 6) (716-877) 56 (918) (819-97.3) 18 (66.7) (46.0-835) 9 (60.0) (323-83.7) 54 (88 5) (778-95 2) 8 IS3.3 (26.6-78.7) Target 1 76 (73.8) (64 2-820) 14 (519) (319-713) Target 2 83 (80.6) (64.2-820) 56 (91.8) (819-973) 18 (667) (46.0-83.5) 9 160.0) (323-83.7) Direct RT-aPCR Method A 79 (76.7) (673-84 5) 53 (86 9) (758-94 2) 16 (593) (388-776) 10 (66.7) (384-88 2) e1 (78.6) (695-061) 55 (90 2) (798-96 3) 9 (60.0) (323-03.7) Method B 17 (63.0) (424-80 6) 80 (777) (684-0s3) 54 (88 5) (778-953 N-1 17 (63.0) (424-80.6) 9 (60.0) (323-83.7) set 48 (78.7) (66.3-88.) 8 (29 6 (13.8-50 2) N-2 63 161.2) (511-70.6) 7 (46.7) (213-73.4) set 52 (SO.5) (405-60.5) 6 (22.2) (8.6- 423) 6 (40.01 (16.3-67.7) Method c 40 (65.6) (523-773) 9 14 8 (70- 26.1) 15 (14.6) (8.4-229) 274) (10- 24.3) N-1 4 (26.7 (78-551) set N-2 51 (49 5) (39.5-59.5) 40 (65,6) 6 (22.21 (6.6- 5 (33.3) (18-616) RT-LAMP 73 (70.9) (611-79.4) 9 (60.0) (323-837) 52 (852) (73.8-93.0) 12 (44 4) (25.5-647) 8 (13.1) (5.8- 24 2) Rapid antigen test 12 1.7) (62-19.5) 2(74) (1.0- 24.3) 2 033) (17-405) LDT, iaboratory-developed test. Method A. SARS-Cov-2direct detection RT-aPCR iet TakaRa Bio inc, Kusatsu, Japan). Method B, Ampdirect 2o19 novel coronavirus detection kit (Snimadzu Corporation, Kyoto, Japan). Method C, SARS-Cov-2 detection kit Toyobo, Osaka, Japan). Primer and probe set recommended by the National institute of infectious Diseases (NID) in Japan Primer and probe set recommended by the Centers for Disease Control and Prevention (CDC) in the United States

A First Course in Probability (10th Edition)
A First Course in Probability (10th Edition)
10th Edition
ISBN:9780134753119
Author:Sheldon Ross
Publisher:Sheldon Ross
Chapter1: Combinatorial Analysis
Section: Chapter Questions
Problem 1.1P: a. How many different 7-place license plates are possible if the first 2 places are for letters and...
See similar textbooks
icon
Related questions
Question

Describe in detail based on the result above

TABLE 1Summary of reciurts of morecuiar alagnostic tests ana tne rapia antigen tast for covID-19 usea on seif-comectea sava sampes Total no. (%) of samples (95% confidence Interval) at the Indicated time of collection since the onset of symptoms Total no. (%) of samples (95%6 confidence Interval) (n - 103) Test and primer set, method, or target Early phase (S9 days) (n - 61) Late phase (-9 days) (n = 27) No specific time (asymptomatic) (n= 15) RT-GPCR LDT 57 (93.4) (84.1-98.2) 17 (63.0) (424-80.6) 84 (81.6) (727-88.) 10 (66.7) (38.4-88.2) 76 (73.8) (64.2-82.0) 54 (88 5) (77.8-95 2) 14 (51.9) (31.9-71.3) 8 (53.3) (26.6-78.7) N-1 set N-2 set 83 (80.6) (71,6-87.7) 57 (93 4) (84.1-98.2) 16 (59 3) (38.8-77.6) 10 (66,7) (38.-88.2) 56 (91.8) (81.9-97.3) 9 (60.0) (323-83.7) cobas SARS-Cov2 83 (80.6) (71.6-877) 18 (66.7) (46.0-83.5) test Target 1 76 (73.8) (64.2-82.0) 54 (88.5) (77.8-95.2) 14 (51.9) (31.9-71.3) 8 (53.31 (26.6-78.7) 56 (91.8) (819-97.3) 18 (66.7) (46.0-83.5) 9 (60.0) (323-83.7) Target 2 83 (B0.6) (64.2-82.0) Direct RT-aPCR Method A 79 (76.7) (673-84 5) 53 (86.9) (758-94 2) 16 (59 3) (38.8-77.6) 10 (66.7) (38.4-88.2) 81 (78.6) (69.5-861) 55 (90.2) (79.8-96 3) 17 (63.0) (424-80.6) 9 (60.0) (323-83.7) Method B 80 (77.7) (68.4-85.3) 54 (88.5) (77.8-95.3) 9 (60.0) (323-83.7) N-1 17 (63.0) (424-80.6) set 63 (61.2) (51.1-706) 48 (78.7) (66.3-88.1) 8 (29 6) (13.8-50.21 7 (46.7) (21.3-734) N-2 52 (S0.5) (405-60.5) 6 (22 2) (8.6- 423) Method co 40 (65.6) (523-773) 6 (40.0) (16.3-67.7) 9 (14.8) (7.0- 26.1) 15 (14.6) (8.4-22.9) 2 (7.4) (1.0- 24.3) N-1 4 (26.7) (7.8-5.1) set N-2 51 (49.5) (39.5-59.5) 40 (65,6) 6 (22 2) (8.6- 5 (33.3) (11.8-61.6) 12 (44.4) (25.5-64.7) RT-LAMP 73 (70.9) (61.1-79.4) 9 (60.0) (323-83.7) 52 (85.2) (73.8-93.0) 8 131) (5.8- 242) Rapid antigen test 12 (1.7) (6.2-19.5) 2 (13.3) (1.7-40.5) 2 (74) (1.0- 24.3) LDT, laboratory-developed test. Method A, SARS-Cov-2 direct detection RT-qPCR kit (TakaRa Bio Inc, Kusatsu, Japan). Method B, Ampdirect 2019 novel coronavirus detection kit (Shimadzu Corporation, Kyoto, Japan). Method C, SARS-COV-2 detection kit (Toyobo, Osaka, Japan). Primer and probe set recommended by the National Institute of infectious Diseases (NIID) in Japan Primer and probe set recommended by the Centers for Disease Control and Prevention (CDC) in the United States
Transcribed Image Text:TABLE 1Summary of reciurts of morecuiar alagnostic tests ana tne rapia antigen tast for covID-19 usea on seif-comectea sava sampes Total no. (%) of samples (95% confidence Interval) at the Indicated time of collection since the onset of symptoms Total no. (%) of samples (95%6 confidence Interval) (n - 103) Test and primer set, method, or target Early phase (S9 days) (n - 61) Late phase (-9 days) (n = 27) No specific time (asymptomatic) (n= 15) RT-GPCR LDT 57 (93.4) (84.1-98.2) 17 (63.0) (424-80.6) 84 (81.6) (727-88.) 10 (66.7) (38.4-88.2) 76 (73.8) (64.2-82.0) 54 (88 5) (77.8-95 2) 14 (51.9) (31.9-71.3) 8 (53.3) (26.6-78.7) N-1 set N-2 set 83 (80.6) (71,6-87.7) 57 (93 4) (84.1-98.2) 16 (59 3) (38.8-77.6) 10 (66,7) (38.-88.2) 56 (91.8) (81.9-97.3) 9 (60.0) (323-83.7) cobas SARS-Cov2 83 (80.6) (71.6-877) 18 (66.7) (46.0-83.5) test Target 1 76 (73.8) (64.2-82.0) 54 (88.5) (77.8-95.2) 14 (51.9) (31.9-71.3) 8 (53.31 (26.6-78.7) 56 (91.8) (819-97.3) 18 (66.7) (46.0-83.5) 9 (60.0) (323-83.7) Target 2 83 (B0.6) (64.2-82.0) Direct RT-aPCR Method A 79 (76.7) (673-84 5) 53 (86.9) (758-94 2) 16 (59 3) (38.8-77.6) 10 (66.7) (38.4-88.2) 81 (78.6) (69.5-861) 55 (90.2) (79.8-96 3) 17 (63.0) (424-80.6) 9 (60.0) (323-83.7) Method B 80 (77.7) (68.4-85.3) 54 (88.5) (77.8-95.3) 9 (60.0) (323-83.7) N-1 17 (63.0) (424-80.6) set 63 (61.2) (51.1-706) 48 (78.7) (66.3-88.1) 8 (29 6) (13.8-50.21 7 (46.7) (21.3-734) N-2 52 (S0.5) (405-60.5) 6 (22 2) (8.6- 423) Method co 40 (65.6) (523-773) 6 (40.0) (16.3-67.7) 9 (14.8) (7.0- 26.1) 15 (14.6) (8.4-22.9) 2 (7.4) (1.0- 24.3) N-1 4 (26.7) (7.8-5.1) set N-2 51 (49.5) (39.5-59.5) 40 (65,6) 6 (22 2) (8.6- 5 (33.3) (11.8-61.6) 12 (44.4) (25.5-64.7) RT-LAMP 73 (70.9) (61.1-79.4) 9 (60.0) (323-83.7) 52 (85.2) (73.8-93.0) 8 131) (5.8- 242) Rapid antigen test 12 (1.7) (6.2-19.5) 2 (13.3) (1.7-40.5) 2 (74) (1.0- 24.3) LDT, laboratory-developed test. Method A, SARS-Cov-2 direct detection RT-qPCR kit (TakaRa Bio Inc, Kusatsu, Japan). Method B, Ampdirect 2019 novel coronavirus detection kit (Shimadzu Corporation, Kyoto, Japan). Method C, SARS-COV-2 detection kit (Toyobo, Osaka, Japan). Primer and probe set recommended by the National Institute of infectious Diseases (NIID) in Japan Primer and probe set recommended by the Centers for Disease Control and Prevention (CDC) in the United States
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 3 steps

SEE SOLUTIONCheck out a sample Q&A here
Blurred answer
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
A First Course in Probability (10th Edition)
A First Course in Probability (10th Edition)
Probability
ISBN:
9780134753119
Author:
Sheldon Ross
Publisher:
PEARSON
A First Course in Probability
A First Course in Probability
Probability
ISBN:
9780321794772
Author:
Sheldon Ross
Publisher:
PEARSON
SEE MORE TEXTBOOKS